Published in Stat Med on July 01, 1989
A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med (1990) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med (1976) 5.86
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 4.26
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med (1992) 3.55
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Speech perception as a function of electrical stimulation rate: using the Nucleus 24 cochlear implant system. Ear Hear (2000) 2.51
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
Evaluation of a new spectral peak coding strategy for the Nucleus 22 Channel Cochlear Implant System. Am J Otol (1994) 2.37
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Characterizing dye bias in microarray experiments. Bioinformatics (2005) 2.15
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst (1992) 2.05
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst (1990) 1.95
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med (1981) 1.92
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med (1995) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion. Mol Cell Biol (1988) 1.81
Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med (1983) 1.79
Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr (1994) 1.79
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst (1994) 1.77
Epidemiology of an international outbreak of Salmonella agona. Lancet (1973) 1.76
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer (1988) 1.75
Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ (1995) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat (1992) 1.74
Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer (1998) 1.72
Intracochlear factors contributing to psychophysical percepts following cochlear implantation. Acta Otolaryngol (1998) 1.68
Electrical stimulation of the auditory nerve: the effect of electrode position on neural excitation. Hear Res (1993) 1.66
Variation in speech perception scores among children with cochlear implants. Ear Hear (2001) 1.64
G-quadruplexes as targets for drug design. Pharmacol Ther (2000) 1.63
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res (1999) 1.63
Evaluation of methods for isolating Salmonella and Arizona organisms from pet turtles. Appl Microbiol (1974) 1.62
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
Clinical findings for a group of infants and young children with auditory neuropathy. Ear Hear (1999) 1.60
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Changing distribution of primary cancers in the large bowel. JAMA (1977) 1.59
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin. Mol Cell Biol (1987) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg (1977) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
Speech perception using a two-formant 22-electrode cochlear prosthesis in quiet and in noise. Acta Otolaryngol (1988) 1.53
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Multiple estrogen receptor assays in human breast cancer. Cancer Res (1983) 1.52
Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res (1993) 1.51
The relationship between speech perception and electrode discrimination in cochlear implantees. J Acoust Soc Am (2000) 1.49
Psychophysical studies with two binaural cochlear implant subjects. J Acoust Soc Am (1997) 1.49
Childhood cancer: nonmedical costs of the illness. Cancer (1979) 1.48
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies. Am J Clin Pathol (1975) 1.48
Cochlear view: postoperative radiography for cochlear implantation. Am J Otol (2000) 1.47
Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones. Br J Cancer (1987) 1.44
Prospective clinical trial of a human tumor cloning system. Cancer Res (1983) 1.44
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
Amplification of c-erbB-2 and aggressive human breast tumors? Science (1988) 1.43
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Profound hearing loss in the cat following the single co-administration of kanamycin and ethacrynic acid. Hear Res (1993) 1.41
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Pitch comparisons of acoustically and electrically evoked auditory sensations. Hear Res (1996) 1.40
Computer-aided three-dimensional reconstruction in human cochlear maps: measurement of the lengths of organ of Corti, outer wall, inner wall, and Rosenthal's canal. Ann Otol Rhinol Laryngol (1996) 1.40
Chronic electrical stimulation of the auditory nerve at high stimulus rates: a physiological and histopathological study. Hear Res (1997) 1.39
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. J Natl Cancer Inst (1990) 1.38
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res (1983) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Short-term auditory memory in children using cochlear implants and its relevance to receptive language. J Speech Lang Hear Res (2002) 1.36
Combined electrical and acoustical stimulation using a bimodal prosthesis. Arch Otolaryngol Head Neck Surg (1993) 1.36
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36